AVIR Stock Analysis: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$5.09
-0.03 (-0.59%)
▼
5d:
-8.62%
30d:
+8.76%
90d:
+39.45%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AVIR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AVIR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $5.09, which is considered slightly low relative to its 30-day fair value range of $4.80 to $5.95.
Technical Outlook: Technically, AVIR is in a strong uptrend. The price is currently testing key support at $5.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVIR is in a strong uptrend. The price is currently testing key support at $5.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.80 -
$5.95
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.5% below Wall St target ($8.83)
- CAUTION: Recommendation downgraded due to -8.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$4.80 -
$5.95
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.05
Resistance Level
$6.19
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.70
Wall Street Target
$8.83
(+72.5%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: March 30, 2026 10:10 AM ET
Data refreshes hourly during market hours. Next update: 11:10 AM
Data refreshes hourly during market hours. Next update: 11:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |